Implanty doszklistkowe w leczeniu zapalenia błony naczyniowej
Intravitreal Implants in the Uveitis Treament
Małgorzata Iwanejko, Marta Misiuk-Hojło
Katedra i Klinika Okulistyki Akademii Medycznej we Wrocławiu Kierownik: prof. nzw. dr hab. n. med. Marta Misiuk-Hojło
Summary: Uveitis is potentially sight-threatening inflammatory eye disease caused by infectious and non-infectious factors for which the standard care involves corticosteroids or immunomodulary therapy (IMT) medicines. Some patients have disease relapse in spite of local and systemic treatment. Poor control of inflammatory episodes caused by medicine dose reduction to minimum because of their side effects, may lead to frequent disease relapses resulting in cumulative damage ? which may lead to cystoid macular edema (CME), retinal detachment, glaucoma and cataract. The goal of the treatment should not only be to suppress inflammation but also to achieve sustained inflammation control until its complete remission and thus prevent permanent cumulative damage. For the last years, intravitreal implants containing fluocinolone acetonide, corticosteroid with slow release has been used in uveitis treatment providing sustained inflammation control and allowing local and systemic therapies reduction or elimination. The main indication for implantation is non-infectious uveitis affecting the posterior segment of the eye. The most common implant side effect is increased intraocular pressure and cataract development. In the study, slowly released fluocinolone acetonide reduced inflammation recurrences and improved or stabilized visual acuity. Intravitreal implant with corticosteroid is effective uveitis treatment and may help to prevent cumulative damage and vision loss.
Keywords: uveitis, treatment, intravitreal implant.